VISION CREATES INNOVATION

AT THE FOREFRONT OF CANCER RESEARCH

Discover Our Pipeline

Keeping Current

Highlights of the 2018 ASCO Annual Meeting

Boston Biomedical is featuring four clinical data poster presentations on investigational compounds napabucasin and DSP-7888 at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting.

Learn More

Two Studies Evaluating WT1 Cancer Peptide Vaccine DSP-7888 (ombipepimut-S*)

Boston Biomedical has initiated dosing of the first patient in each of two clinical studies evaluating DSP-7888, an investigational cancer peptide vaccine.

Learn More

LEADING RESEARCH & DEVELOPMENT OF NOVEL THERAPEUTICS

Discover Our Science

CanStem 111P Trial

A Trial of Napabucasin (BBI-608) Plus Weekly Nab-paclitaxel With Gemcitabine in Adult Patients With Metastatic Pancreatic Ductal Adenocarcinoma (PDAC).

Learn More

CanStem 303C Trial

A Trial of Napabucasin (BBI-608) in Combination With FOLFIRI in Adult Patients With Previously Treated Metastatic Colorectal Cancer (mCRC).

Learn More

WIZARD 201G Trial

A Trial of DSP-7888 Dosing Emulsion in Combination With Bevacizumab Versus Bevacizumab Alone in Adult Patients With Recurrent or Progressive Glioblastoma.

Learn More

Join Our Team

The Boston Biomedical Difference

We’re out to transform cancer care and make a meaningful difference in the lives of oncology patients. With cutting-edge science, unwavering commitment, and robust resources, we’re making it our mission to forge new territory in the fight against cancer.

Learn More

A ROLE IN CANCER RECURRENCE & METASTASIS

Learn More